1. Home
  2. XFOR vs PLBY Comparison

XFOR vs PLBY Comparison

Compare XFOR & PLBY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • XFOR
  • PLBY
  • Stock Information
  • Founded
  • XFOR 2014
  • PLBY 1953
  • Country
  • XFOR United States
  • PLBY United States
  • Employees
  • XFOR N/A
  • PLBY N/A
  • Industry
  • XFOR Biotechnology: Biological Products (No Diagnostic Substances)
  • PLBY Recreational Games/Products/Toys
  • Sector
  • XFOR Health Care
  • PLBY Consumer Discretionary
  • Exchange
  • XFOR Nasdaq
  • PLBY Nasdaq
  • Market Cap
  • XFOR 118.4M
  • PLBY 138.1M
  • IPO Year
  • XFOR N/A
  • PLBY N/A
  • Fundamental
  • Price
  • XFOR $1.61
  • PLBY $1.71
  • Analyst Decision
  • XFOR Strong Buy
  • PLBY Buy
  • Analyst Count
  • XFOR 3
  • PLBY 2
  • Target Price
  • XFOR $72.33
  • PLBY $1.85
  • AVG Volume (30 Days)
  • XFOR 1.8M
  • PLBY 339.1K
  • Earning Date
  • XFOR 08-11-2025
  • PLBY 08-12-2025
  • Dividend Yield
  • XFOR N/A
  • PLBY N/A
  • EPS Growth
  • XFOR N/A
  • PLBY N/A
  • EPS
  • XFOR 2.16
  • PLBY N/A
  • Revenue
  • XFOR $31,364,000.00
  • PLBY $116,691,000.00
  • Revenue This Year
  • XFOR $1,300.08
  • PLBY $3.84
  • Revenue Next Year
  • XFOR N/A
  • PLBY $2.70
  • P/E Ratio
  • XFOR $0.74
  • PLBY N/A
  • Revenue Growth
  • XFOR N/A
  • PLBY N/A
  • 52 Week Low
  • XFOR $1.38
  • PLBY $0.52
  • 52 Week High
  • XFOR $26.83
  • PLBY $2.44
  • Technical
  • Relative Strength Index (RSI)
  • XFOR 40.77
  • PLBY 43.25
  • Support Level
  • XFOR $1.55
  • PLBY $1.83
  • Resistance Level
  • XFOR $2.22
  • PLBY $1.88
  • Average True Range (ATR)
  • XFOR 0.20
  • PLBY 0.09
  • MACD
  • XFOR 0.06
  • PLBY -0.03
  • Stochastic Oscillator
  • XFOR 26.44
  • PLBY 7.50

About XFOR X4 Pharmaceuticals Inc.

X4 Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in the research and development of novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It has the ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.

About PLBY PLBY Group Inc.

PLBY Group Inc connects consumers around the world with products, services, and experiences to help them look good, feel good, and have fun. PLBY Group serves consumers in four categories: Style and Apparel, Digital Entertainment and Lifestyle, Sexual Wellness, and Beauty and Grooming. It operates through three segments Direct-to-Consumer, Licensing, and Digital Subscriptions and Content. It generates revenue through the sales of products and content services to consumers.

Share on Social Networks: